
Opinion: Are FDA plans enough to boost inclusivity within clinical trials?
DDW Editor Reece Armstrong examines whether recent FDA plans to boost diversity within clinical trials are enough to tackle the scale of the problem. In June this year, the US Food and Drug Administration (FDA) issued draft guidance designed to help boost the engagement of underrepresented communities within clinical… Read More


